2 news items
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
VIR
5 Mar 24
regarding Vir's strategy and plans; the potential benefits, safety and efficacy of tobevibart and elebsiran for the treatment of chronic hepatitis delta
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
VIR
22 Feb 24
earned in 2023.
Benefit from (Provision for) Income Taxes
- Prev
- 1
- Next